Cite
HARVARD Citation
Schumann, K. et al. (2023). Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. Journal of the European Academy of Dermatology and Venereology. pp. 894-906. [Online].